Ohio – A proposal advancing through the Ohio Legislature has become the center of a growing political battle, with supporters describing it as a patient safety measure and opponents arguing it is a new attempt to restrict access to abortion medication without explicitly saying so.
House Bill 324, known as the Patient Protection Act, never mentions abortion in its text. Even so, both supporters and critics largely agree that one of its biggest effects would be to make obtaining abortion pills more difficult.
The legislation would require Ohio’s health director to create a state list of prescription drugs considered high-risk. Any medication found to cause severe adverse effects in more than 5% of users would face additional restrictions before patients could obtain it.
The bill specifically points to serious complications such as hemorrhaging, infection, and sepsis as examples of severe adverse effects.
At the center of the debate is mifepristone, a medication commonly used in medication abortions and approved by the Food and Drug Administration years ago. Supporters of the proposal argue that research shows the drug carries risks significant enough to justify additional oversight. Critics counter that the evidence being used is deeply flawed and that the legislation is designed primarily to create obstacles for women seeking abortions.
Why Mifepristone Is at the Center of the Debate
Supporters of the bill frequently cite a study released in April 2025 by the Ethics & Public Policy Center. Based on data involving more than 800,000 patients, the study concluded that mifepristone had an adverse event rate of nearly 11%. If that figure were accepted by state regulators, the medication would easily exceed the bill’s proposed 5% threshold and likely be placed on Ohio’s watch list.
Once placed on that list, obtaining the drug would become a more complicated process. Patients would be required to attend an in-person appointment, receive warnings from a physician regarding potential risks, and schedule a follow-up visit before completing treatment. Supporters say those additional steps would improve patient safety and ensure better medical oversight.
Critics, however, argue that the requirements would create significant barriers, especially for Ohio residents living in rural areas where access to healthcare is already limited. In southeastern Ohio, many people rely heavily on telehealth services because of transportation challenges and long distances to medical facilities. Additional appointments could also increase costs for lower-income patients who may struggle to take time off work, arrange transportation, or pay for repeated visits.
Dispute Over the Science
A major point of disagreement centers on the study being used to justify the proposal. Opponents note that the Ethics & Public Policy Center report was not peer-reviewed and relied heavily on insurance claims data. They argue that insurance claims do not necessarily prove severe complications occurred.
According to critics, patients often seek follow-up care for routine concerns, questions about normal bleeding, or reassurance after taking medication. Those visits can generate insurance claims even when no serious medical emergency exists. Opponents have also challenged some of the study’s categories, including broad labels such as “ER Visit” and “Other abortion-specific complications.”
While the legislation focuses on severe outcomes such as infection and sepsis, critics note that the actual number of those specific complications was much smaller than the overall figures highlighted by supporters. Backers of the proposal respond that the study only counted incidents classified as Grade 3, meaning severe, and Grade 4, meaning life-threatening. They argue that lower-level events were excluded from the analysis.
Still, opponents maintain that classification choices matter and that not every hospital visit automatically reflects a dangerous complication. They also point out that the findings stand apart from numerous other studies that have reached different conclusions regarding the safety of mifepristone.
Supporters Say the Bill Is About Safety
During testimony before lawmakers, supporters repeatedly insisted that the legislation is focused on protecting patients rather than restricting abortion.
Ohio Right to Life Director Carrie Snyder argued that telehealth prescribing can sometimes leave patients without adequate follow-up care. “We’ve also heard reports of medicines like that being prescribed without very good follow up at all,” said Ohio Right to Life Director Carrie Snyder. “And one case in particular was someone was struggling with suicidal thoughts after taking this. And then the provider actually just doubled the dose, rather than having some kind of in-person visit and actually digging into what the problem was. They doubled the dose and that person actually committed suicide. So just very tragic things that, in my view, are preventable with good public policy around telehealth.”
Snyder also defended the bill’s threshold for identifying high-risk medications. “But when you have these, you know, the threshold being 5%, when things are shown to be dangerous with very serious hemorrhaging, sepsis, those type of things that require hospitalization, that there just needs to be a better care around that both before and after that takes place,” Snyder said.
Opponents Call It a Backdoor Abortion Restriction
Opposition to the legislation has been extensive. Roughly 50 individuals and organizations submitted testimony against the bill, including Planned Parenthood Advocates of Ohio.
Danielle Firsich, the organization’s director of public policy, argued that the proposal allows state officials to rely on evidence that falls short of accepted scientific standards. “So literally written into the bill, it does not require actual peer reviewed research published in scientific journals to determine the efficacy or the safety of medication,” said Danielle Firsich, director of public policy for Planned Parenthood Advocates of Ohio.
She added, “So, they’re literally saying, OK, there are hundreds of peer reviewed, published, accredited research studies that show the efficacy and safety of mifepristone. But if you can find one, if you can find one that says it has a higher adverse impact rate, the director of health can use that to limit access to the medication entirely. That is not science or medically based.”
Firsich was especially critical of the study being used by supporters. “The study they’re using was self-published and not peer reviewed, and it was so flawed that it has been debunked by every major medical organization. And they have refused to release their data set, so it can’t be replicated or tested. I mean, I could effectively go on to a blog tomorrow and write a self-published research study about whatever I wanted and insist that there’s a higher adverse impact rate.”
Unlike mifepristone, emergency contraception commonly known as Plan B would not be affected because it does not require a prescription.
The legislation has already passed the Ohio House and is now under review by the Senate Health Committee. After two hearings, lawmakers are expected to continue debating the proposal as both sides prepare for what could become one of Ohio’s most closely watched healthcare and abortion-related battles of the year.
